Aptima® Chlamydia trachomatis Assay

Protect and improve the reproductive and sexual health of patients through accurate and early detection of Chlamydia trachomatis (CT).

Assay box in lab background




    Protecting Reproductive & Sexual Health

    The single target Aptima Chlamydia trachomatis assay provides excellent diagnostic performance across a broad range of specimen types, from both patient and clinician collected samples. This assay adds additional testing flexibility by using an alternative target region to the Aptima Combo 2® assay (for CT/NG), providing more confidence in diagnosis.1,2

    Clarity & Confidence in Every Diagnosis

    The CE-marked assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs, a preferred specimen for CT testing.1

    Confidence in Diagnosis

    The alternate target Aptima CT assay can be used for reflex testing on reactive Aptima Combo 2 samples when additional analysis is required.3

    High Sensitivity & Specificity

    A molecular NAAT (Nucleic Acid Amplification Test) that targets rRNA to ensure excellent assay sensitivity with proven assay performance. Provides an upfront biological advantage compared with assays that detect DNA, as there is up to 1,000-fold more rRNA than DNA per cell.4

    Improve Workflow & Assay Consolidation

    Benefit from efficient workflow, reduced hands-on time and sample volume scalability, by running assays on the fully automated Panther® System.5

    Female lab technician observing Panther systems in lab setting

    Simplify & Scale the Future of Diagnostics

    The Aptima CT Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population level screening.

    Proven Performance

    Alternate target testing for confidence in Chlamydia trachomatis results.1

    16s rRNA target

    Chlamydia trachomatis (CT)

    Sensitive and specific

    performance across a wide range of sample types

    Symptomatic and asymptomatic

    testing possible

    Aligned With UK National Guidelines

    "In medico-legal cases, for best practice, a reactive NAAT result should be confirmed using a different target to ensure reproducibility."6

    Gloved hand holding vial rack in a lab setting

    One Sample, Multiple STI Results

    Clinically relevant sample type options make the Aptima CT Assay easy to order as a standalone or in combination with other assays from the automated Hologic STI Solution. Browse relevant collection devices below.

    Man and woman holding hands at outdoors

    Protect Fertility With Accurate Testing

    Chlamydia (CT) can have serious long-term consequences, including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.7 Accurate testing and treatment are critical to protecting sexual and reproductive health.

    Evidence. Insight. Collaboration.

    Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

      1. Aptima Chlamydia trachomatis Assay [Package Insert] 502184EN Rev. 010. Hologic Inc., 2022
      2. Aptima Combo 2 Assay. [package insert]. AW-19693-001 Rev. 001. Hologic, Inc., 2020
      3. AW-26055-001 Rev. 001  Panther / Panther Fusion Operators Manual 
      4. Chernesky M, Jang D, Luinstra K, et al. High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J Clin Microbiol. 2006;44(2):400- 405.
      5. Ratnam S, Jang D, Gilchrist J et.al.  Workflow and Maintenance Characteristics of Five Automated Laboratory Instruments for the Diagnosis of Sexually Transmitted Infections.  J. Clin. Microbiol. 2014;52(7):2299-2304
      6. Nwokolo NC, Dragovic B, Patel S, et al. 2015 UK national guideline for the management of infection with Chlamydia trachomatis.Int J STD AIDS. 2016 Mar;27(4):251-67.
      7. Workowski KA, Bachman LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70



      Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.

      Notified Body number wherever applicable